The following is a guide to learn more about a number of clinical trials that are taking place at pharmaceutical and medical device companies who are a part of HOPA’s Industry Relations Council (IRC). To learn more about all active clinical trials, visit www.clinicaltrials.gov.
Iovance
- NSCLC – LUN-202 - A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung
- Solid Tumor Trial – NCT03645928 – A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
- Cervical Cancer - NCT03108495 - A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
- CLL/SLL - NCT04155710 - A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Iovance Clinical Trials
- Iovance Clinical Trials
Servier
Morphosys
Lilly
BeiGene
BTG Specialty Pharmaceuticals
- Clinical Trials with glucarpidase in adult Osteosarcoma
- Clinical Trials with glucarpidase and CNS Lymphoma
- Clinical Trials with glucarpidase fir active or at high risk of CNS Lymphoma
ADC Therapeutics
